• 仪器无忧网首页
首页 >  仪器无忧网品牌优搜库 >  W > 威高

中国 . 威高

logo

威高

威海威高 www.weigaoholding.com  www.weigaogroup.com  www.wgbio.cn www.wegortho.com
山东威高集团医用高分子制品股份有限公司(「本公司」)及其附属公司(「本集团」)主要从事研发、生产及销售医用耗材、骨科材料、心脏支架等。本公司为国家高技术研究发展(863)计划成果产业化基地、国家级高新技术企业。本集团主要生产基地位于山东省威海市。


本集团在中国注册,拥有一个由18个销售办事处及21个客户联络中心和107多家城市代表处组成的庞大销售网络,并已建立广泛的客户基础,其产品销售予5,400多家医疗单位和分销商,其中包括医院2800多家、血站400多家、其它医疗单位700多家和逾1,500家贸易公司。

本集团生产的产品种类多达150余种,产品规格超过5000种,产品可分为六大系列,即1)一次性使用医疗耗材及原料,其中包括输液(血)器、注射器、血袋与血液成份分离耗材、采血系列耗材、齿科耗材和麻醉系列耗材等,以及医用PVC粒料和非PVC粒料等;2)骨科材料及工具,主要包括钢板、螺钉等创伤治疗耗材、脊柱系列耗材及正在发展的人工关节系列耗材;3)医用针制品,主要包括静脉针、注射针、留置针、采血针、异形针等系列制品;4)血液净化系列耗材,主要包括穿刺针、血液回路管、透析器等肾科耗材,以及用于红斑狼疮、器官移植排异反应、类风湿关节炎等免疫系统疾病治疗的免疫吸附柱,以及其它正在研发和注册的LDL吸附柱、内毒素吸附柱和乙肝病毒吸附柱等;5)心脏支架产品,主要包括药物涂层心脏支架、球囊等;6)用于药品包装的预充式注射器。
“国家高技术研究发展(863)计划成果产业化基地”、“国家级企业技术中心”,并建有企业博士后工作站。公司积极开展产、学、研合作,与中科院长春应用化学研究所、中科院大连化学物理研究所、中科院沈阳金属研究所、第三军医大学、301医院、哈工大(威海)等科研院所、院校紧密合作,并聘请了10位两院院士做顾问,依托其人才和科研力量,异地建立了九个威高集团研发中心,立足行业制高点,消化吸收国际前沿技术,开发具有自主知识产权的高科技产品。公司有60多个产品达到国内外先进水平,不少产品填补了国内空白,20个产品入选国家863计划、国家重点火炬计划、国家高技术产业示范化工程、国家级重点新产品等国家各类项目,其中药物涂层支架系统、预充式注射器、骨科植入材料等产品打破了国外公司对中国市场的垄断。
集团注重产品品牌的长远发展,强调其产品质量。自2001年11月以来,集团的一次性使用无菌输液器、一次性使用无菌输血器及一次性使用无菌注射器的生产及服务的质量体系获中国医疗器械质量认证中心授予ISO9001:2000认证、中国CMD认证。从1999年12月,集团的输液器、输血器、一次性使用注射器及塑料血袋等产品种类获得由TÜV Product Service Gmbh颁发的CE认证证书以来,本集团已先后获得一次性使用自动取血器、一次性使用CT增强注射器造影剂针筒、一次性使用自毁式安全注射器、自动缩回式安全注射器、骨科器械、金属接骨板,脊柱内固定系统,金属接骨螺钉、带锁髓内钉、一次性使用无菌注射针、一次性使用静脉留置针、无针密闭输液接头等产品及体系的CE认证。于2003年12月5日,集团的产品质量检查中心获中国实验室国家认可委员会评为符合国家测试及定标规定。于2005年6月23日,集团拥有的 商标被中国国家工商行政管理总局认定为中国国内医疗器械行业第一个中国驰名商标。
目前,集团的销售主要在中国市场,本集团正积极开拓国际市场,产品已经出口美国、德国、罗马尼亚、澳大利亚和英国等30个国家和地区。
威海威高坐落在美丽的海滨城市威海。集团下辖18个子公司,其中山东威高集团医用高分子制品股份有限公司为香港上市公司,已经形成了医疗器械、药品、航天电子、投资、房地产等五大业务领域齐头并进的发展格局。集团现有总资产40多亿元,员工9000多人,厂区占地面积125万平方米,拥有符合GMP要求的净化车间20多万平方米,可生产300多个品种近30000种规格的医疗器械、药品等产品。
20年来,威高坚持“开拓、创新、求实、巩固”的建厂方针,以科技创新为动力,以科学管理为后盾,促进了企业的持续、快速、健康发展。公司较早在国内开发了一次性使用输注耗材、手术缝合线、植入性医用导管、心脏支架、留置针及各种异型针、血液净化系列产品、骨科系列产品、机电一体化医疗器械、治疗型注射液、生物诊断试剂、人造血浆等医疗器械产品和药品,建立了极具规模的医疗用品工业园、骨科材料工业园、医药科技工业园、航天电子产品生产基地,现已成为中国最大的一次性使用医疗器械制造商。
威高集团坚持“以人为本、科技先行”的发展战略,健全科学的管理模式,完善管理体系。公司在同行业中率先引进和使用ERP、KPI等先进管理软件,产品通过了CE、ISO9001、ISO13485、3C等认证,部分产品通过了美国FDA上市许可。公司的检测中心通过了国家实验室认可委员会的认可。对科技的执着追求,使威高集团获得了生存发展空间。公司被国家科技部等部委确定为“国家火炬计划重点高新技术企业”、“国家高技术研究发展(863)计划成果产业化基地”、“国家级企业技术中心”,并建有企业博士后工作站。公司积极开展产、学、研合作,与中科院长春应用化学研究所、中科院大连化学物理研究所、中科院沈阳金属研究所、第三军医大学、301医院、哈工大(威海)等科研院所、院校紧密合作,并聘请了10位两院院士做顾问,依托其人才和科研力量,异地建立了九个威高集团研发中心,立足行业制高点,消化吸收国际前沿技术,开发具有自主知识产权的高科技产品。公司有60多个产品达到国内外先进水平,不少产品填补了国内空白,20个产品入选国家863计划、国家重点火炬计划、国家高技术产业示范化工程、国家级重点新产品等国家各类项目,其中药物涂层支架系统、预充式注射器、骨科植入材料等产品打破了国外公司对中国市场的垄断。
威高集团坚持不懈地实施名牌战略,培育知名品牌。“洁瑞”商标被认定为“中国驰名商标”,“洁瑞牌一次性使用无菌输注医疗器械”被授予“中国名牌产品”称号,“洁瑞”品牌被中国品牌研究院评定为中国医疗器械第一品牌。公司在全国30多个省、市、自治区建立了100多个销售办事机构,同全国7000多家医院、400多家血站、1800多家商业公司建立了长期稳定的关系。公司产品不仅畅销到国内30多个省、市、自治区,还直接出口到美国、欧盟、俄罗斯、南非、巴西等50多个国家和地区。
威高集团将始终如一地坚持科学发展观,以“携同白衣使者,开创健康未来”为宗旨,以一次性医疗器械和药品为主导,大力推进产业结构、产品结构、体制结构的调整,实现资本、技术和管理的国际化,矢志成为具世界竞争力、亚洲领先、最受人尊敬的医疗器械和医药企业,为促进我国医疗事业发展,提高人民健康水平做出新的贡献。


威高集团有限公司
地址: 山东省威海市世昌大道312号 
邮政编码: 264209 
电话: 0631-5620486 
传真: 0631-5620555 
Email: scb@weigaogroup.com 
网址: http://www.weigaoholding.com

Weigao Holding Company Limited. (“Weigao Holding”) and together with its subsidiaries (“Weigao”)is situated in Weihai City, a picturesque coastal city in China. Weigao Holding has 18 subsidiaries and has more than 9,000 employees and a total asset value of over RMB 4 billion (approximately US$0.59 billion). Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”), the major subsidiary of Weigao Holding, was listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited in 2004. Weigao covers a manufacturing area of 1,250,000 square meters including sterilized workshops with an area of 200,000 square meters that comply with GMP standards. It currently produces more than 250 types of medical products with more than 30,000 specifications.
In the past 20 years, Weigao rooted with the spirit of “development, innovation, pragmatism and consolidation”, and dedicated to attract talented people from the communities. Weigao focuses on technology driven innovative ideas and scientific management to transform the development mode and to advance the healthy and efficient growth of the business. In the domestic market, the company was the early mover to initiate the products of single use transfusion sets, medical suture, implantable medical catheters, coronary stents, intravenous catheters, irregular needles, blood purification, orthopaedic, electronic and mechanical medical products, medical injection fluid products, diagnostic reagents, artificial blood plasma and various medical products and medications. Weigao has established very large manufacturing bases in China for medical consumables, orthopaedic products, pharmaceuticals,and aerospace products. Today, Weigao is the leading single use medical consumable manufacturer in China.
Weigao established the mode of scientific management to achieve a smooth operation system. It is the first company in the industry to introduce and to successfully establish the management system of enterprise resource planning (ERP), key performance indicators (KPI) and other management system. Weigao Holding obtained the certifications of Conformité Européene (CE), ISO9000, ISO13485, China Compulsory Certification; and products registration of FDA 510K from Food and Drug Association (FDA). The award accredited to testing and inspection center of the company is also the only certification issued by China National Accreditation Board for Lab oratories in industry.
Weigao is devoted to innovation, technology and people and its commitment to technology is the value to its development. Weigao was accredited by the State Science and Technology Commission as the “Key High Technology & New Technological Enterprise under the State Torch Program”, the “Preferred Manufacturing Base for New Products Developed by the State High Technology Research Development (863) Program, and the technology center was also notarized by national governmental authorization as “State Enterprise Technology Center”. Weigao continues to develop into a conglomerate enterprise comprising of duties and responsibilities of manufacturing, education and research. The company established a post-doctoral research working center and collaborated with scientific research institutions and universities with strong scientific and research strength in setting up nine research and development centers. Ten academicians were appointed as consultants. There are more than 60 types of products which are further developed to enhance to an international level, and many of which filled the domestic blank. The company engaged in more than 20 national projects including Project 863, Project Torch, Model Project of National High Tech, The Key Technology Innovation Program of the State, and other projects. Currently, Weigao plays roles in the market of drug eluting stent (DES), pre-filled syringes and orthopedic material which were previously dominated by international players.
Weigao has been persistently sustain its brand value . The “Jierui” trademark is notarized by State Administration for Industry & Commerce as “China Famous Brand”; the “Jierui Single Use Sterile Infusion and Syringe Medical Device” was accredited by General Administration of Quality Supervision, Inspection and Quarantine of China as “the Most Famous Branded Product in China”; it is also notarized by China Brand Academy as “The No.1 Trademark” in the industry. Weigao has an extensive coverage of over 100 representative offices in 30 provinces, municipality and autonomous regions in China. Long term reliable relationship has also been well established with more than 7,000 hospitals, over 400 blood stations, and over 1800 other medical units. Today, Weigao’s products are not just the best-selling products in the domestic market; they are also exported to more than 50 countries and regions, including the United States, European countries, Russia, South Africa, and Brazil.
Weigao will continue to strive without reserve for the scientific development, and the mission is to “work with physicians to create healthy life for people in future”. Weigao will continue to improve and adjust the business structure, products mix and organizational structure. The goal of Weigao is to gradually transform from a domestic manufacturer to an internationally competitive, leading in Asia, and respectable conglomerate. Weigao, standing as a leading medical device company, continues to create and sustain a high level of performance in medical device products and pharmaceuticals. Weigao is well-positioned to continuing serving the medical community and improve people’s health for generations to come.